Could CBD ease chronic pain? new trial seeks answers

NCT ID NCT03984565

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a high-CBD, low-THC sublingual product against a placebo in 25 adults with chronic pain conditions like arthritis or injury-related pain. Over 9 weeks, researchers will track pain levels, medication use, quality of life, and thinking skills to see if CBD offers real relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cannabidiol (CBD)

What this could lead to

If it works, this could point toward a non-addictive option for managing chronic pain and reducing reliance on conventional painkillers.

What could go wrong

This is a small, early-phase trial with only 25 participants. The results may not apply to everyone, and CBD may not outperform placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Pain chronic pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • McLean Hospital

    RECRUITING

    Belmont, Massachusetts, 02478, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••